Journal article icon

Journal article

Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector.

Abstract:

BACKGROUND: Vaccine development in human Plasmodium falciparum malaria has been hampered by the exceptionally high levels of CD8(+) T cells required for efficacy. Use of potently immunogenic human adenoviruses as vaccine vectors could overcome this problem, but these are limited by preexisting immunity to human adenoviruses. METHODS: From 2007 to 2010, we undertook a phase I dose and route finding study of a new malaria vaccine, a replication-incompetent chimpanzee adenovirus 63 (ChAd63) enco...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Publisher's version

Actions


Access Document


Files:
Publisher copy:
10.1093/infdis/jir850

Authors


More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Clinical Medicine, Jenner Institute
Role:
Author
More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Clinical Medicine, Jenner Institute
Role:
Author
More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Clinical Medicine, Jenner Institute
Role:
Author
More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Clinical Medicine, Jenner Institute
Role:
Author
More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Clinical Medicine, Jenner Institute
Role:
Author
Expand authors...
Wellcome Trust More from this funder
National Institute for Health Research More from this funder
Publisher:
Oxford University Press Publisher's website
Journal:
The Journal of infectious diseases Journal website
Volume:
205
Issue:
5
Pages:
772-781
Publication date:
2012-03-05
DOI:
EISSN:
1537-6613
ISSN:
0022-1899
URN:
uuid:bb773bd0-2a3f-49d7-aa9c-592b20127387
Source identifiers:
245860
Local pid:
pubs:245860

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP